The U.S. Food and Drug Administration''s Endocrinologic and Metabolic Drugs Advisory Committee has approved Arena Pharmaceuticals'' and Eisai''s new obesity drug Lorcaserin. Word came from the FDA on May 10 and both Arena and Eisai say they''re thrilled to continue developing the drug. Locraserin is an investigational drug that provides weight loss and maintenance to people who are clinically overweight and obese. The drug acts as a selective serotonin 2C receptor agonist, according to a press release. "The advisory committee''s positive vote supports our belief in lorcaserin as a potential new treatment option for the medical management of overweight and obesity," said Jack Lief, Arena''s President and Chief Executive Officer. "We will continue to work with the FDA as the agency completes its review of the lorcaserin new drug application." Visit: http://www.rttnews.com/1885691/fda-approves-new-obesity-drug-locraserin.aspx?type=hnr&utm_source=google&utm_campaign=sitemap